303 related articles for article (PubMed ID: 12377195)
1. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
2. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
4. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
[TBL] [Abstract][Full Text] [Related]
5. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation.
Pan PY; Gu P; Li Q; Xu D; Weber K; Chen SH
J Immunol; 2004 Apr; 172(8):4779-89. PubMed ID: 15067054
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
7. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
8. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation.
Kim YJ; Stringfield TM; Chen Y; Broxmeyer HE
Blood; 2005 Jan; 105(1):274-81. PubMed ID: 15353478
[TBL] [Abstract][Full Text] [Related]
11. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
12. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
15. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
16. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
17. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
Dawicki W; Bertram EM; Sharpe AH; Watts TH
J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
[TBL] [Abstract][Full Text] [Related]
19. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
